Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART

PHASE1TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
HIV-1
Interventions
BIOLOGICAL

MVA.HIVconsv low dose

Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10\^8 pfu at week 0, 4 and 12.

OTHER

Placebo low dose

Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.

BIOLOGICAL

MVA.HIVconsv high dose

Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10\^8 pfu at week 0, 4 and 12.

OTHER

Placebo high dose

Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.

Trial Locations (2)

OX3 9DS

Weatherall Institute of Molecular Medicine, Oxford

OX3 7LJ

Oxford Genitourinary Medicine, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

lead

University of Oxford

OTHER